TSE:CURA

Curaleaf Holdings Inc (CURA.TO)

16.21
+1.00 (6.57%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
119 watching
0
Investor Insights
star iconJun 8, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Curaleaf Holdings Inc. (CURA-T) is navigating the volatile cannabis sector, which is experiencing significant fluctuations in response to evolving political landscapes and potential cannabis rescheduling. Experts highlight that while the company has suffered from past spikes and subsequent declines in stock price due to excitement and disappointment regarding regulatory changes, its leaders maintain that Curaleaf, alongside its peers, will be well-positioned as the industry matures and expands across the U.S. and Europe. Concerns linger about current tax restrictions which impede the sector's growth, but there's optimism that these challenges will eventually be addressed. With improved management and cleaned-up balance sheets, the broader cannabis sector is seen as undervalued and primed for attention. Nonetheless, the unpredictable nature of the business climate necessitates caution, making it advisable to hold only small positions until cash flow stabilizes.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Trulieve, TCNNF
TOP PICK
Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)
BUY
It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.
TOP PICK
Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)
HOLD
He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.
BUY
CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.
Showing 31 to 35 of 35 entries